Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Comparing Adalimumab and Placebo in Adult Japanese Subjects With Rheumatoid Arthritis
Brief Summary: To evaluate the potential of adalimumab to inhibit radiographic progression in joint destruction compared with placebo in adult Japanese subjects with recent onset of rheumatoid arthritis.


Options:
A: Arm Label: CNTO 148 50 mg + methotrexate; Type: EXPERIMENTAL; Interventions: Drug: CNTO 148, Drug: Methotrexate (MTX) | Arm Label: CNTO 148 100 mg + methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate (MTX) | Arm Label: Placebo + methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate (MTX) | Intervention Type: DRUG; Name: CNTO 148; Assigned to Arm(s): CNTO 148 50 mg + methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + methotrexate | Intervention Type: DRUG; Name: Methotrexate (MTX); Assigned to Arm(s): CNTO 148 100 mg + methotrexate, CNTO 148 50 mg + methotrexate, Placebo + methotrexate
B: Arm Label: Group 1: Placebo + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Placebo injections, Drug: Methotrexate capsules, Biological: Golimumab 50 mg injections, Biological: Golimumab 100 mg injections | Arm Label: Group 2: Golimumab 100 mg + Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo capsules, Drug: Methotrexate capsules, Biological: Golimumab 50 mg injections, Biological: Golimumab 100 mg injections | Arm Label: Group 3: Golimumab 50 mg + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate capsules, Biological: Golimumab 50 mg injections, Biological: Golimumab 100 mg injections | Arm Label: Group 4: Golimumab 100 mg + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate capsules, Biological: Golimumab 50 mg injections, Biological: Golimumab 100 mg injections | Intervention Type: DRUG; Name: Placebo injections; Assigned to Arm(s): Group 1: Placebo + Methotrexate | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): Group 2: Golimumab 100 mg + Placebo | Intervention Type: DRUG; Name: Methotrexate capsules; Assigned to Arm(s): Group 1: Placebo + Methotrexate, Group 2: Golimumab 100 mg + Placebo, Group 3: Golimumab 50 mg + Methotrexate, Group 4: Golimumab 100 mg + Methotrexate | Intervention Type: BIOLOGICAL; Name: Golimumab 50 mg injections; Assigned to Arm(s): Group 1: Placebo + Methotrexate, Group 2: Golimumab 100 mg + Placebo, Group 3: Golimumab 50 mg + Methotrexate, Group 4: Golimumab 100 mg + Methotrexate | Intervention Type: BIOLOGICAL; Name: Golimumab 100 mg injections; Assigned to Arm(s): Group 1: Placebo + Methotrexate, Group 2: Golimumab 100 mg + Placebo, Group 3: Golimumab 50 mg + Methotrexate, Group 4: Golimumab 100 mg + Methotrexate
C: Arm Label: Sequence 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Sequence 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Sequence 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: CP-690,550 | Arm Label: Sequence 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 3 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 4 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 4
D: Arm Label: DB Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double-blind Placebo | Arm Label: DB adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Double-blind adalimumab | Arm Label: DB Adalimumab/OL Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Double-blind adalimumab, Biological: Open-label Adalimumab | Arm Label: DB Placebo/OL Adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Double-blind Placebo, Biological: Open-label Adalimumab | Arm Label: DB Adalimumab/RE OL Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Double-blind adalimumab, Biological: Open-label Adalimumab, Biological: Open-labelAdalimumabRescue | Arm Label: DB Placebo/RE OL Adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Double-blind Placebo, Biological: Open-label Adalimumab, Biological: Open-labelAdalimumabRescue | Intervention Type: BIOLOGICAL; Name: Double-blind adalimumab; Assigned to Arm(s): DB Adalimumab/OL Adalimumab, DB Adalimumab/RE OL Adalimumab, DB adalimumab | Intervention Type: DRUG; Name: Double-blind Placebo; Assigned to Arm(s): DB Placebo, DB Placebo/OL Adalimumab, DB Placebo/RE OL Adalimumab | Intervention Type: BIOLOGICAL; Name: Open-label Adalimumab; Assigned to Arm(s): DB Adalimumab/OL Adalimumab, DB Adalimumab/RE OL Adalimumab, DB Placebo/OL Adalimumab, DB Placebo/RE OL Adalimumab | Intervention Type: BIOLOGICAL; Name: Open-labelAdalimumabRescue; Assigned to Arm(s): DB Adalimumab/RE OL Adalimumab, DB Placebo/RE OL Adalimumab

Answer: D